Drugs for Hearing Loss: A Sound Opportunity
This article was originally published in Start Up
Executive Summary
Hearing loss is an arena largely ignored by the biopharmaceutical industry, with most of the innovation coming from med-tech players. That situation is ripe for change as a vanguard of start-ups is attempting to develop novel therapies to treat a variety of hearing disorders, including Ménière's disease and sudden sensorineural hearing loss.
You may also be interested in...
Otonomy Sustained-Release Gels May Solve Ear Med Delivery Problems
Otonomy has moved two candidates into registration trials for middle and inner ear disorders and plans to have a third ready for the clinic next year.
New GSK Spin-Out Targets Hearing Loss
The second spin-out to emerge after GSK's 2010 exit from neurosciences-related R&D, Autifony Therapeutics may receive up to 10 million pounds in Series A funding to develop preclinical assets for hearing disorders.
New GSK Spin-Out Targets Hearing Loss
The second spin-out to emerge after GSK's 2010 exit from neurosciences-related R&D, Autifony Therapeutics may receive up to 10 million pounds in Series A funding to develop preclinical assets for hearing disorders.